ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Interventional therapeutic strategies for metastatic liver cancer].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Metastatic liver cancer is a common terminal manifestation of malignant neoplasms, with colorectal cancer liver metastasis (CRLM) being particularly prevalent. Surgical resection is applicable only to a small proportion of patients. In recent years, interventional therapy has become an important local treatment modality for patients with unresectable metastatic liver cancer, offering advantages such as minimal invasiveness, precision, and repeatability, thus supporting downstaging, bridging, and salvage therapy. The role of interventional therapy is shifting from terminal palliative care toward a systematic therapeutic strategy within a multidisciplinary comprehensive management framework, emphasizing individualized stratification based on tumor burden, hepatic function, and therapeutic objectives to facilitate intrahepatic tumor burden reduction, create a window for radical treatment, and enhance long-term patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.